Abstract
Bone marrow was the traditional graft source when we introduced these procedures to South Africa. Technical details were established using rabbits as the experimental model with translation into a formally structured clinical programme at the University of Cape Town, based in the Groote Schuur Hospital, in 1972. Lack of any infrastructure was overcome by the acquisition of the first continuous-flow cell separator in sub-Sahara to provide for granulocyte transfusions. This was shortly followed by creating a dedicated platelet donor panel and establishing a specialized laboratory for clonogenic assays, flow cytometry, and programmed freezing and by including cryopreservation. Development was constant and seamless but four distinct periods are recognizable. First, guided and constantly encouraged by Professor E Donnall Thomas, was the use of an unfractionated mononuclear population derived from multiple sternal and iliac crest aspirations where complications, as in other centres, included rejection and, particularly troublesome, acute as well as chronic GVHD. The second was centred on CsA in association with Professor Jean Borel at Sandoz in Basle, leading to a decrease in the incidence and severity of the latter immunologic phenomena but not to their abrogation. Third was the opportunity of working with Professor Herman Waldmann and Dr Geoff Hale, first in Cambridge and latterly in Oxford, on immunosuppression achieved by ex vivo T-cell depletion within the broad ambit of the Campath users group. It was here that there was pioneered the alternative new approach of adding the anti-CD 52 MoAb only to the graft in what has become known as the in-the-bag technique. The fourth, securely based on early laboratory and clinical experiences, was a switch to the use of PBSCs mobilized into the circulation with stimulatory peptides. In 1995, this original transplant team relocated to a new academic centre in the private sector and has continued to actively refine the programme over the subsequent decade: the facility at Groote Schuur hospital continues independently. Early recognition that accountability for these expensive and high profile procedures was an important obligation led to consecutive transplants being reported to the International and Autologous registries and now continuing to the Centre for Bone Marrow Transplant Research concurrently with the European Bone Marrow Transplant Registry. This disciplined approach has ensured that all data undergo constant audit and, on such a basis, underpin the unbroken accreditation extending over more than three and a half decades. With difficulties in finding sibling donors, a further achievement was the creation of The South African Bone Marrow Registry and now a proposal to also start a national transplant registry that will complement the survey currently being conducted, on a worldwide basis, by the European Group for Blood and Marrow Transplantation. It is concluded that a properly constituted and functioning multidisciplinary team can cost-effectively carry out immunohematopoietic stem cell grafting even in an under-resourced country with an outcome approximating that reported from recognized First World reference centres. The caveat is that, outside such comprehensive units, results may be less impressive, thereby arguing for resource allocation being directed to academically designated, rather than incentive-driven, preferred providers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292: 832–843.
Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975; 292: 895–902.
Forman SJ . Planning and management for related and unrelated donor transplantation: day 10 to day 100. Blood Marrow Transplant Rev 2007; 17: 5–7.
Wingard J . Current strategies and future concepts for prophylactic therapy. Blood Marrow Transplant Rev 2007; 17: 5–8.
Loberiza Jr FR, Zhang MJ, Lee SJ, Klein JP, LeMaistre CF, Serna DS et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood 2005; 105: 2979–2987.
Loberiza Jr FR, Serna DS, Horowitz MM, Rizzo JD . Transplant center characteristics and clinical outcomes after hematopoietic stem cell transplantation: what do we know? Bone Marrow Transplant 2003; 31: 417–421.
Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550–1558.
Claessens JJ, Beerendonk CC, Schattenberg AV . Quality of life, reproduction and sexuality after stem cell transplantation with partially T-cell-depleted grafts and after conditioning with a regimen including total body irradiation. Bone Marrow Transplant 2006; 37: 831–836.
Cilley J, Winter JN . Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas. Haematologica 2006; 91: 114–120.
Jacobs P, Wood L, Fullard L, Waldmann H, Hale G . T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant 1994; 13: 763–769.
Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 2006; 37: 1003–1008.
Hogan WJ, Little MT, Zellmer E, Friedetzky A, Diaconescu R, Gisburne S et al. Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. Biol Blood Marrow Transplant 2003; 9: 489–495.
Standards for haematopoietic progenitor cell collection, processing and transplantation. The Joint Accreditation Committee of ISCT-EBMT, 2nd edn. 2005. http://www.jacie.org.
European Federation for Immunogenetics. http://www.efiweb.org.
Lee S . Routine long-term follow-up of hematopoietic cell transplantation survivors. Blood Marrow Transplant Rev 2007; 17: 9–10.
Jacobs P, Wood L . Immunohaematopoietic stem cell transplantation in South Africa: the first 40 years—an experimental and clinical model for approaching restorative medicine. Specialist Forum 2006; 6: 34–43.
Chandy M, Srivastava A, Dennison D, Mathews V, George B . Allogeneic bone marrow transplantation in the developing world: experience from a center in India. Bone Marrow Transplant 2001; 27: 785–790.
Creemers P, Jacobs P, Bird A, Du Toit E . The South African Bone Marrow Donor Registry. S Afr Med J 1993; 83: 819–821.
Fouillard L, Labopin M, Gratwohl A, Powles R, Bacigalupo A, Bego G et al. Outcome of 5651 hematopoietic stem cell transplants for hematological malignancies carried out in Europe in 1993: a reliability study of the registry. Bone Marrow Transplant 2001; 30: 813–831.
Wood L, Hester JP, Jacobs P . Apheresis—from theory to practice. CME 1993; 11: 1127–1134.
Jacobs P . Effect of cyclosporin A on the incidence of graft-versus-host disease (GVHD) and survival of rabbits following allogeneic bone marrow transplantation. In: Baum SJ, Ledney GD, Khan A (eds). Experimental Hematology Today 1981. Karger: Basel, 1981, pp 87–96.
Jacobs P, Eglin L . Cyclosporin A. Current status, including the Cape Town experience. In: Fenichel RL, Chirigos MA (eds). Immune Modulation Agents and their Mechanisms. Marcel Dekker Inc.: New York, 1984, pp 191–228.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trial in Chronic Graft-versus-Host Disease. I. Diagnosis and Staging Working Group. Biol Blood Marrow Transplant 2005; 11: 945–955.
Chao NJ, Chen BJ . Prophylaxis and treatment of acute graft-versus-host disease. Semin Hematol 2006; 43: 32–41.
Jacobs P, Bareford D, Parker JR, Milns B, Manuel G . An evaluation of cyclosporin A in reducing the incidence of graft-versus-host disease in rabbits undergoing allogeneic bone marrow transplantation. Sandoz Medical Bulletin 1980; 9: 32–35.
Funke VAM, de Medeiros CR, Setubal DC, Ruiz J, Bitencourt MA, Bonfim CM et al. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant 2006; 37: 961–965.
Barge RM, Starrenburg CW, falkenburg JH, Fibbe WE, Marijy EW, Willemze R . Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath ‘in the bag’ as T-cell depletion: the Leiden experience. Bone Marrow Transplant 2006; 37: 1129–1134.
Barendse G, Tailford R, Wood L, Jacobs P . The effect of peptide stimulation on haematopoietic stem cell mobilization including engraftment characteristics and a note on donor side effects. Transfus Apheresis Sci 2005; 32: 105–116.
Jacobs P, Wood L . Bone marrow transplantation in the private sector. S Afr Med J 2000; 90: 321–322.
Wood L, Jacobs P . Bone marrow transplantation. Department of Haematology and Bone Marrow Transplantation Unit. Constantiaberg Medi-Clinic: Plumstead, 2002.
Jacobs P, Wood L, Borrill V, Schlaphoff T, du Toit ED . Unrelated bone marrow transplantation in South Africa: a single centre experience. 5th South African Haematopoietic Stem Cell Transplantation Symposium, Cape Town, 2–3 March 2007.
Wood L, Juritz J, Havemann J, Lund J, Waldmann H, Hale G, Jacobs P . Paediatric immunohaematopoietic stem cell transplantation in Cape Town: a private academic centre programme (in press).
Jacobs P, Wood L, Haveman J, Juritz J . Adult immunohaematopoietic stem cell transplantation in Cape Town: a private academic centre ten year experience (Forthcoming).
Wood L, Robinson R, Gavine L, Juritz J, Jacobs P . Single unit lymphoma experience: outcome in a Cape Town academic centre. Transfus Apher Sci 2007; 37: 93–102.
Wood L, Armitage JO, Diehl V, Fuchs M, Jacobs P . Transplantation in the lymphomas. Specialist Forum 2007; 7: 22–33.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jacobs, P., Wood, L. Immunohematopoietic stem cell transplantation: introduction and 35 years of development in South Africa—the historical and scientific perspective. Bone Marrow Transplant 42 (Suppl 1), S125–S132 (2008). https://doi.org/10.1038/bmt.2008.140
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.140